Profusa starts board-led review of strategic options to boost shareholder value and advance European product approval.

Profusa, a digital health company, announced its Board of Directors has launched a process to explore strategic alternatives such as partnerships, business combinations, or asset sales to maximize shareholder value. The company is focusing on near-term goals including advancing CE Mark approval for its Lumee Oxygen platform in Europe and growing revenue from its Healthcare Research business. Profusa has engaged Tungsten Advisors to assist in identifying and executing potential strategic opportunities. The process aims to strengthen the company's scale, execution, and long-term growth prospects, but no specific transaction is guaranteed yet.